You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Correction: Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

Article Text

Article menu

See original article:

Download PDFPDF

XML
Correction
Correction: Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

http://dx.doi.org/10.1136/jitc-2020-001089corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Montesarchio V, Parrella R, Iommelli C, et al. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. J Immunother Cancer 2020;8:e001089. doi: 10.1136/jitc-2020-001089.

    This paper has been corrected since it was published online. The author name Roberto Parrella was incorrectly spelt as Roberto Parella.